ISTH 2021 Congress
Hemophilia and Rare Bleeding Disorders » Novel Biotherapeutics in Hemophilia
Theme Navigation
- ISTH 2021 Congress
- Hemophilia and Rare Bleeding Disorders
- Novel Biotherapeutics in Hemophilia
- Hemophilia and Rare Bleeding Disorders
-
Abstract Number: OC 32.1
Ex vivo Assessment of the Importance of Activated Factor IX (FIXa) Levels in the Procoagulant Effect of Recombinant FIX Concentrates in Emicizumab-treated Patients
-
Abstract Number: OC 48.1
A Blood Coagulation Factor IX Variant that Functions Independently of Factor VIII Mitigates the Hemophilia A Phenotype in Patient Plasma
-
Abstract Number: PB0682
A Systematic Review on the Pharmacokinetics and Associated Pharmacodynamics of Emicizumab in Humans
-
Abstract Number: PB0675
Administration of fVIII Protein through Human Placental Cells Reduces the Risk of an Antibody Response in Juvenile Sheep
-
Abstract Number: LPB0116
An Accurate and Simple Liquid Chromatography Tandem Mass-spectrometric Method for the Quantification of Emicizumab in People with Hemophilia A
-
Abstract Number: PB0678
Cost-effectiveness Analysis of the Brazilian Immune Tolerance Induction Protocol with Recombinant Factor VIII and Prophylaxis with Bypassing Agents or Emicizumab
-
Abstract Number: PB0686
Do New Therapies alter the Treatment of Hemophilia Patients?
-
Abstract Number: PB0684
Emi and Me: The Real-world Impact of Emicizumab on the Lives of People with Haemophilia A with Inhibitors and their Families
-
Abstract Number: PB0681
Emicizumab Assays: One Stage vs. Chromogenic Stage Assay
-
Abstract Number: OC 49.2
Emicizumab: Will it Suffice for Bone Metabolism?
-
Abstract Number: PB0679
Measuring the Chromogenic FVIII Mimetic Activity of the New Bispecific Antibody, Mim8, in Artificially Spiked Severe Haemophilia A Plasma
-
Abstract Number: PB0680
Measuring the FVIII Mimetic Activity of the New Bispecific Antibody, Mim8, in Severe Haemophilia A Plasma Using APTT and One-stage FVIII Assays
-
Abstract Number: OC 48.4
Orally Delivered Factor VIII Restores Hemostasis in a Hemophilia A Dog
-
Abstract Number: PB0677
Real-world Experience of Emicizumab Treatment Using Entire Vials Only
-
Abstract Number: OC 08.4
Real-world Use of Damoctocog Alfa Pegol in Patients with Hemophilia A: Analysis of PK Profiles and Treatment Regimen Data from the WAPPS-Hemo Database
-
Abstract Number: PB0687
Successful Experience of Emicizumab Prophylaxis in a Child with Severe Hemophilia A and Inhibitor without Previous Immune Tolerance Induction
-
Abstract Number: PB0676
Tailoring the Effect of Antithrombin-targeting Therapy in Hemophilia A Using in Silico Thrombin Generation
-
Abstract Number: LPB0117
The Association of Emicizumab and rFVIIa for Major Orthopaedic Surgery
-
Abstract Number: PB0674
The Effect of rFVIIa and Mim8 Combination in Hemophilia A-like Blood